Magdalena is an internationally recognised and award-winning researcher. Her focus is on developing practical and affordable vaccines and treatments for complex diseases like malaria and cancer. She has also pioneered the use of synthetic size-defined non-inflammatory nanoparticles in vaccines.
Magdalena has forged a stellar career in medical and health research. She came to Australia from Oxford University in the UK, where she showed new ways in which malaria parasites can trick the human immune system. More recently, her insights have been used to help understand cancer progression across multiple human clinical trials, particularly leukemia and ovarian cancer.
Magdalena is also the director of the Biomedical and Health Innovation Enabling Impact Platform.
Kirsty is interested in studying the effects of vaccines on the immune system, in both human clinical trials and animal models. Over the past ten years, Kirsty has also been generating and testing nanoparticles as vaccine delivery systems and investigating how they interact with specific cell types to enhance the immune response.
Jennifer is actively fostering the use of Big Data at RMIT by co-founding the RMIT Bioinformatics network, providing bioinformatics literacy through user group meetings, workshops and symposia, and by lecturing bioinformatics to both graduate and undergraduate students. Her research focuses on the immunomodulatory effects of both conventional and nanoparticle-based vaccines in the context of infectious disease and (brain) cancer using systems vaccinology and big data approaches.
April obtained her PhD in Medicine from Utrecht University, The Netherlands. Her doctoral work focused on iron metabolism and age-related inflammation. She further was a California Institute of Regenerative Medicine fellow at University of California, Los Angeles, working on endoderm specification and beta cell regeneration for diabetes. Currently, April is applying her previous knowledge to understand immune-epigenetic processes in age-related diseases, and help development of diagnosis, prognosis and treatment for ovarian cancer.
David is an ARC DECRA fellow, Victoria fellow and RMIT Vice-Chancellor’s Postdoctoral fellow. He is also an Honorary Fellow in the Dept of Microbiology and Immunology and the Dept of Chemical Engineering at the University of Melbourne. He completed his PhD at The University of Melbourne in 2017 with Prof. Frank Caruso and subsequently undertook a Research Fellow position in the same group exploring various low-fouling nanomaterials for controlled bio–nano interactions. He was also a co-leader (2017–2021) of the signature project ‘Mediating Protein Interactions’ within the ARC Centre of Excellence in Convergent Bio–Nano Science and Technology. In 2021, he moved to RMIT University to take up a Vice-Chancellor’s Postdoctoral Fellowship in the CAVA laboratory where he investigates how nanomaterials interact with immune systems.
Jessica is a clinical informatician who specialises in clinically appropriate machine learning. Her research utilizes advanced analytics and machine learning techniques to investigate cancers of older people, colorectal cancer and ageing, aspirin and cancer, medications and cancer, and pharmacogenomics.
Monica has a background in biochemistry and molecular biology, and completed a PhD in immunology at Monash University in 2013. She has since worked post-doctorally in the areas of neuroscience and complementary medicine before joining the CAVA laboratory in 2018.
Pooria is a RMIT Vice-Chancellor's Postdoctoral Research Fellow and a recipient of the esteemed Fulbright Postdoctoral Fellowship (2023-2024) at MIT's Koch Institute for Integrative Cancer Research. With a PhD in biomedical engineering from the University of Sydney (2022) and degrees in materials science, his work focuses on pioneering fluorescent nanoparticles for medical applications. He combines materials science, nanotechnology, and cell biology to devise nanoparticle systems for precise disease detection and therapy.
Georgia completed a Masters in Zoology/Genetics (Animal Reproduction) at University of Melbourne (2015), while working as a First Year Biology Tutor and Practical Demonstrator (2014-2016). She then moved to Monash University to work as a Research Assistant and Department Safety Officer in the Physiology Department (2016-2019). She joined the CAVA Laboratory as a Laboratory Administrator in late 2019 and was promoted to Senior Technical Officer in 2021.
Srinivasa received his M.S. (Pharmacy) from the National Institute of Pharmaceutical Education & Research (NIPER- Hyderabad, India) in 2010 and PhD from RMIT University, Australia in 2015. His doctoral research focused on the synthesis of bioactive small heterocyclic molecules for cancer chemotherapy and targeted drug delivery. Since 2015, he is working as a Postdoctoral Fellow at RMIT university. His current research involves development of a new class of metal-based drugs for ovarian cancer treatment with superior selectivity and activity towards cancer cells, including otherwise drug-resistant cancer cells.
Rhiane joined the CAVA Laboratory in 2018 as a PhD candidate, completing her studies in 2023. With a background in immunology, Rhiane is interested in studying autoreactive immune cells in different disease contexts, with current projects investigating autoreactivity in both COVID-19 and cancers such as ovarian cancer.
Cyril studied at Claude Bernard University in Lyon, France and completed his Masters studies at Sanofi Pasteur, developing new adjuvants designed to boost the innate immune system to protect patients having surgery from nosocomial disease. Upon moving to Australia, he joined ONJCRI, applying his skills to the field of immunotherapy in the big fight against cancer. Cyril subsequently joined the CAVA laboratory, where he predominantly works on clinical trials in ovarian cancer treatment; hoping to find the key to unlock the immune system and to reveal the secret to improving treatment outcomes.
Jack completed his PhD at Monash University in 2022 investigating the immunomodulatory capacity of hypertension and diabetes, with a specific focus on the diabetic retina. Jack is interested in extending his work through investigating the effects of vaccines on the immune system in human clinical trials.
Emily's PhD project focuses on characterising immune-based prognostic biomarkers to improve treatment outcomes in ovarian cancer.
Joshuah’s fascination with immunology stems from its immense translational potential and he is especially interested in understanding mechanisms of immune regulation in health and disease. His current project involves studying the immune response to SARS-CoV-2, its emerging variants, and COVID-19 vaccines. With a focus on the adaptive B and T cell responses, his main topics include immune cross-reactivity and cytokine-mediated regulation of the host response during COVID-19 infection.
Suyama completed her Master's degree in Advanced Convergence Technology and Science at Jeju National University, South Korea, where she honed her expertise in the field. Currently, Suyama is immersed in her PhD project, which centres on "Understanding the Role of Protein Corona on Nanoparticle-Cell Interactions for Improved Nanomedicine." Her research delves into the crucial interplay between nanoparticles and cellular components, with a particular focus on the pivotal role played by protein coronas.
Namita's PhD project focusses on immune response of T cells in cancer therapy.
Anamika's project encompasses the interdisciplinary fields of nanotechnology and biomedical science. The study integrates particle nanoengineering, proteomics analysis, and whole blood assays to investigate the effect of biomolecular corona on nanoparticle-cell interactions for the development of advanced nanomedicine. Her research endeavours to comprehend the relationships between nanoparticle design, biomolecular corona composition, and the association of nanoparticles with immune cells.
Our research group sits within the ‘Translational Immunology and Nanotechnology’ (TIN) Theme. This theme was created to drive innovation in omics/precision medicine, nanotechnology and point-of-care devices.
Acknowledgement of Country
RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business - Artwork 'Sentient' by Hollie Johnson, Gunaikurnai and Monero Ngarigo.
Acknowledgement of Country
RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business.